Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. News
  7. Summary
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agenus : to Provide Corporate Update and Second Quarter 2021 Financial Report

07/26/2021 | 04:05pm EDT

LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and to provide a corporate update.

Conference Call
Dial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International).
Conference ID number: 3686849.

Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/gsbikqz2.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies through its MiNK Therapeutics subsidiary (formerly AgenTus Therapeutics), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com


Primary Logo

Source: Agenus Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about AGENUS INC.
09/17AGENUS : ESMO 2021 - Agenus Presents Updates on Balstilimab Plus Zalifrelimab Combination
PU
09/17ABCELLERA BIOLOGICS : Health Care Stocks Down to End Week
MT
09/17Health Care Stocks Mixed Premarket Friday
MT
09/17AGENUS : Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 T..
MT
09/16Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in..
GL
09/14INSIDER SELL : Agenus
MT
09/10AGENUS : New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Co..
AQ
09/10Agenus Inc. Announces New Subsidiary, SaponiQx
CI
09/09AGENUS : to Participate in September Investor Conferences
AQ
09/07AGENUS : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to..
MT
More news
Analyst Recommendations on AGENUS INC.
More recommendations
Financials (USD)
Sales 2021 263 M - -
Net income 2021 -95,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,8x
Yield 2021 -
Capitalization 1 417 M 1 417 M -
Capi. / Sales 2021 5,38x
Capi. / Sales 2022 14,3x
Nbr of Employees 359
Free-Float 87,2%
Chart AGENUS INC.
Duration : Period :
Agenus Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,08 $
Average target price 10,00 $
Spread / Average Target 64,5%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Jennifer S. Buell President & Chief Operating Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Marc van Dijk Chief Technology Officer
Steven OĺDay Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.91.20%1 417
MODERNA, INC.335.15%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.38%50 254
CELLTRION, INC.-20.75%33 124
SEAGEN INC.-5.09%30 241